These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 27008697)
1. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression. Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697 [TBL] [Abstract][Full Text] [Related]
2. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422 [TBL] [Abstract][Full Text] [Related]
3. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis. Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208 [TBL] [Abstract][Full Text] [Related]
4. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism]. Rahimian A; Barati G; Mehrandish R; Mellati AA Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579 [TBL] [Abstract][Full Text] [Related]
5. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718 [TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362 [TBL] [Abstract][Full Text] [Related]
7. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331 [TBL] [Abstract][Full Text] [Related]
8. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model. Guo Y; Fan Y; Pei X Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729 [TBL] [Abstract][Full Text] [Related]
10. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway. Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845 [TBL] [Abstract][Full Text] [Related]
12. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity. Almacellas-Rabaiget O; Monaco P; Huertas-Martinez J; García-Monclús S; Chicón-Bosch M; Maqueda-Marcos S; Fabra-Heredia I; Herrero-Martín D; Rello-Varona S; de Alava E; López-Alemany R; Giangrande PH; Tirado OM Cancer Lett; 2020 Apr; 474():1-14. PubMed ID: 31911079 [TBL] [Abstract][Full Text] [Related]
13. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma. Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063 [TBL] [Abstract][Full Text] [Related]
14. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587 [TBL] [Abstract][Full Text] [Related]
15. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283 [TBL] [Abstract][Full Text] [Related]
16. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364 [TBL] [Abstract][Full Text] [Related]
17. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025 [TBL] [Abstract][Full Text] [Related]
18. Salidroside ameliorated hypoxia-induced tumorigenesis of BxPC-3 cells via downregulating hypoxia-inducible factor (HIF)-1α and LOXL2. Chen X; Kou Y; Lu Y; Pu Y J Cell Biochem; 2020 Jan; 121(1):165-173. PubMed ID: 31162697 [TBL] [Abstract][Full Text] [Related]
19. Extracellular ATP promotes breast cancer invasion and epithelial-mesenchymal transition via hypoxia-inducible factor 2α signaling. Yang H; Geng YH; Wang P; Zhou YT; Yang H; Huo YF; Zhang HQ; Li Y; He HY; Tian XX; Fang WG Cancer Sci; 2019 Aug; 110(8):2456-2470. PubMed ID: 31148343 [TBL] [Abstract][Full Text] [Related]
20. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]